Tesamorelin vs CJC-1295

Side by side

Tesamorelin High and CJC-1295 Medium are both analogues of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to release growth hormone. Both are modified to last longer than natural GHRH, which is broken down within minutes. WADA's 2026 List names both among the growth hormone-releasing factors ¹. The table is read from our encyclopedia entries.

Two ways to make GHRH last

CJC-1295 was designed to hitch a ride on albumin, the most abundant protein in blood. Chemists attached a reactive group to a GHRH fragment so that it binds albumin within minutes of injection; in rats the best version gave four times the growth hormone of unmodified GHRH over two hours and remained in plasma beyond 72 hours ². In healthy adults its half-life was 5.8 to 8.1 days ³.

Tesamorelin takes a smaller step: it is the full 44-amino-acid GHRH with a fatty-acid-derived group added to the front end to resist the enzyme that breaks it down. It still clears quickly; the current labels give a half-life of 8 to 11 minutes after a dose under the skin, so it is injected daily ¹. In a pooled pharmacokinetic analysis, age, body size, race and HIV status did not change how it was handled ⁴.

Tesamorelin: what the trials showed

Tesamorelin's approval rests on large trials in people with HIV whose antiretroviral treatment had left excess fat around the abdominal organs. In 806 people randomised to daily tesamorelin or placebo, visceral fat fell by 24 cm² on the drug and rose by 2 cm² on placebo over 26 weeks, a treatment effect of 15.4%, without loss of fat under the skin; triglycerides fell and IGF-1 rose ⁵. People who stayed on it kept the loss to week 52, and it came back after stopping ⁶.

Later trials explored liver fat. In 61 people with HIV and fatty liver, a year of tesamorelin cut liver fat by 4.1 percentage points more than placebo ⁷. A 2026 meta-analysis of five randomised trials found reductions in visceral fat, trunk fat, liver fat and waist size, and a lean-mass gain of 1.42 kg, with joint and muscle pain, tingling and injection-site redness among the side effects ⁸. In people with type 2 diabetes, 12 weeks did not worsen diabetes control ⁹.

CJC-1295: two small studies

CJC-1295's human evidence is two studies from 2006. In two randomised, placebo-controlled trials in healthy adults aged 21 to 61, a single injection raised mean growth hormone two- to tenfold for six days or more and IGF-1 1.5- to threefold for 9 to 11 days; repeated doses kept IGF-1 above baseline for up to 28 days, with no serious adverse reactions reported ³. In healthy young men, it left the timing and size of growth hormone pulses unchanged but raised trough levels 7.5-fold and IGF-1 by 45% ¹⁰.

That is where development stopped. No trial tested it for any disease. According to our entry, its US compounding nomination was withdrawn, and FDA records serious adverse events associated with it, including increased heart rate and a systemic vasodilatory reaction ¹. It turns up in seized preparations and bodybuilding use ¹¹, and a study of forum discussions found women using it for weight loss, muscle and skin alongside other image drugs ¹².

Why one was approved and the other was not

The two molecules do much the same thing at the pituitary. What separates them is that one was taken through phase 3 trials for a specific condition with a measurable outcome, visceral fat on a CT scan, and the other was not. That is the general story of the growth hormone peptides: the chemistry is often similar, and the evidence and regulatory status are not. A week-long half-life also has a downside the studies do not resolve: if something goes wrong, the drug cannot be stopped quickly.

How the differences add up (as of October 3, 2026)

Tesamorelin is an approved medicine with large trials behind one narrow use, abdominal fat in HIV-associated lipodystrophy; its label does not cover weight loss, anti-ageing or performance. CJC-1295 is a research chemical with two small studies in healthy people and no approval anywhere. Both are prohibited in sport ¹. Doses in the studies cited are not recommendations; our tesamorelin vs sermorelin and CJC-1295 vs sermorelin comparisons set each beside the oldest GHRH analogue.

Frequently asked questions

Is tesamorelin the same as CJC-1295?

No. Both are GHRH analogues, but tesamorelin is the full GHRH molecule with a protective group, cleared in minutes and FDA-approved; CJC-1295 is a GHRH fragment that binds albumin, lasts about a week and was never approved.

What is tesamorelin approved for?

To reduce excess abdominal fat in adults with HIV who have lipodystrophy. It is not approved for general weight loss or anti-ageing.

How long does CJC-1295 last?

In healthy adults its half-life was 5.8 to 8.1 days, because it binds to albumin in the blood.

Related on Grey Peptides

• Tesamorelin
• CJC-1295
• Tesamorelin vs Sermorelin

Sources

1. Grey Peptides dataset records for both compounds (status, half-life and studied doses as sourced on each entry); read October 2, 2026.
2. Jetté, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-8. PMID: 15817669
3. Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
4. González-Sales, M., et al. (2015). Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet, 54(3), 285-94. PMID: 25358450
5. Falutz, J., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab, 95(9), 4291-304. PMID: 20554713
6. Falutz, J., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719-28. PMID: 18690162
7. Stanley, T. L., et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 6(12), e821-e830. PMID: 31611038
8. Badran, A. S., et al. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract, 20(1), 2-12. PMID: 41545261
9. Clemmons, D. R., et al. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One, 12(6), e0179538. PMID: 28617838
10. Ionescu, M., et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12), 4792-7. PMID: 17018654
11. Henninge, J., et al. (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal, 2(11-12), 647-50. PMID: 21204297
12. Van Hout, M. C., et al. (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse, 51(1), 73-84. PMID: 26771670

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.